Next Generation Technologies for Drug Discovery In Cancer Image Professor Ted Hupp - Chair of Cancer Research Research in a Nutshell Cancer progression is driven in part by the mutation of genes that mediate immortality, angiogenesis, metastasis, changes in energy metabolism, and evasion of the immune system. P53 mutation is one of the most common genetic changes in cancer development that leads to a re-wiring and selective survival advantage to the developing cancer cell. This genetic re-wiring involves changes in the transciptome, the proteome, and the phenotype of the cell within a specific microenvironmental niche in vivo. The lab is using biophysical, biochemical, and proteomic approaches to develop novel molecular insights into clinically relevant cancer progression pathways; particularly cancers of unmet clinical need including oesophageal adenocarcinoma and sarcomas. Emerging therapeutic strategies being developed include drugging protein-protein interactions; biologics and immunotherapeutics; and proteogenomics platforms that define mutated neoantigen landscapes to facilitate cancer vaccine developments. Research Programme People Ted HuppPrincipal Investigator and Professor of Cancer ResearchKamila PawlickaPhD StudentEstefania EspositoPhD StudentVanessza FentorStudentSinem GulPhD StudentMishal TariqPhD StudentContactTed.Hupp@ed.ac.uk Ted Hupp - Research Information CollaborationsProf Mark Arends, University of EdinburghProfessor David Argyle, University of Edinburgh Professor Kathryn Ball, University of Edinburgh Professor Neil Carragher, University of EdinburghProfessor Rebecca Fitzgerald, Cambridge UniversityMr Graeme Grimes, University of EdinburghDr Larry Hayward, University of EdinburghDr Doug Houston, University of Edinburgh Dr Rob O’Neill, University of EdinburghIan Overton, University of EdinburghProfessor Donald Salter, University of EdinburghProfessor Colin Semple, University of Edinburgh Dr Borek Vojtesek, Masaryk Cancer Institute, BrnoProfessor Malcolm Walkinshaw, University of Edinburgh Professor Nick Westwood, St Andrews UniversityProfessor Siva Umapathy, Indian Instutute for Science, BangalorePartners and FundersBBSRCMedical Research ScotlandThe Technology Strategy Board British CouncilEuropean Union Development FundWellcome TrustCancer Research UKScientific ThemesCancer, monoclonal antibodies, protein-protein interactions, proteogenomics, vaccines.Technology ExpertiseProtein science, post-translational modifications, phage antibody libraries, RNA editing, p53 pathway science, and proteogenomics. This article was published on 2024-09-23
